20 March 2026
Swissmedic: Revision of Chapter 20 and 21 of the Pharmacopoea Helvetica 13
In order to clarify the distinction between manufacture and preparation for administration under therapeutic products legislation, Swissmedic urgently amended the Good Manufacturing Practice rules for small quantities of medicinal products in the Swiss Pharmacopoeia (Ph. Helv.), effective 1 June 2025. These provisions have now undergone further revision. The updated chapters 20 and 21 will be included in the forthcoming edition of the Pharmacopoea Helvetica, with publication scheduled for October 2026.
For more information, see here.
More News
-
-
Swissmedic: New strategic Approach to minimizing Animal Testing in the Development of Medicinal Products
-
Swissmedic: The new Pharmacopoea Helvetica 13
-
European Medicines Agency: New oral GLP-1 Medicine for Weight Management and Type 2 Diabetes
-
FOPH: Capital Income of Health Insurers for Premium Reduction – current voluntary System deemed sufficient
-
Decision C-6534/2024 of 13 October 2026
-
Swissmedic: Haemovigilance Annual Report 2025
-
Swissmedic: GMP Compliance by foreign Manufacturers - Simplifications for Industry and Clarification of unresolved Issues
-
European Medicines Agency: Clinical Trial Applications Advice Pilot becomes permanent
-
European Medicines Agency: Highlights of the September 2026 Management Board meeting